Faheem Hasnain
At a glance: Faheem Hasnain is Director at Kura Oncology (KURA). Their latest SEC Form 4, filed Dec 10, 2025, reported a sale of $110K. On file: 0 purchase lines ($0) and 1 sale line ($110K).
Disclosed holdings: about $175K of KURA stock: 23,983 shares reported on their latest Form 4 (filed Dec 10, 2025), valued at the Nov 19, 2026 close of $7.31. This counts only KURA shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Kura Oncology, Inc. (KURA)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Faheem Hasnain's InsiderPrint
6 trades from SEC Form 4 filings, 2020 to 2025, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $300K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (5)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- T. Michael GlennDirector · PNR · 99% match
- Julie DillDirector · STRL · 96% match
- Herbert K. ParkerDirector · NVT · 96% match
- Sravan Kumar EmanyCFO · BEAM · 95% match
- Atul PandeDirector · IMVT · 93% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Dec 10SEC | KURAKura Oncology, Inc. | Sell Plan | 10,00023,983 held (−29%) | $10.98 | $110K | -33.4% |
- Sell
Director Faheem Hasnain sold $110K of KURA at $10.98 — cuts the stake by 29%; pre-scheduled 10b5-1 plan sale.
Follow Faheem Hasnain
Get one email when Faheem Hasnain files a new purchase or sale. Free.
At most one email a day about Faheem Hasnain, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.